Compare Paychex, Inc. (PAYX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Paychex, Inc. trades at $109.38 (market cap $38.58B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Paychex, Inc. is far larger — about 7.7× Travere Therapeutics Inc. Common Stock's market cap, and Paychex, Inc. pays a 4.39% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PAYX | TVTX | |
|---|---|---|
Market Cap | $38.58B | $5.02B |
Volume | 2,721,004 | 2,060,842 |
Sector | Industrials | Health |
52-Week High | $127.54 | $67.52 |
52-Week Low | $85.57 | $26.79 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $42.26B | $5.15B |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $106.26, up 1.55% today, with a bullish technical signal despite some bearish moving average indicators. The company reported a beat on Q2 2026 EPS of $1.34 versus $1.32 expected, continuing a trend of earnings outperformance. Revenue grew to $5.57B in 2025, with strong profitability margins including a 27.35% net income margin and 47.06% ROE. Recent news highlights dividend sustainability concerns amid a stock price decline, though the company maintains a solid financial position.
The outlook for PAYX is mixed; fundamentals remain robust with consistent earnings beats and high profitability, but investor sentiment is cautious due to valuation concerns and labor market exposure. Near-term price action hinges on Q3 2026 earnings and dividend coverage metrics. Risks include economic sensitivity and competitive pressures, while analyst consensus suggests modest upside to a $111 price target.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
